The steadfast advance of the synthetic biology field has enabled scientists to use genetically
engineered cells, instead of small molecules or biologics, as the basis for the development …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …

Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are
considered as specialized immune cells that can be genetically modified to obtain capable …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid
tumors is crucial for tumor clearance. We engineered CAR-T cells to express interleukin (IL) …

T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic
agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the …

Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically
engineered to express chimeric antigen receptors (CAR) constitute the most clinically …

Background: Cancer is one of the leading causes of death worldwide. Over the years, a
number of conventional cytotoxic approaches for neoplastic diseases has been developed …